REFERENCES
- Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328.
- Nakagawa O, Ogawa Y, Itoh H, Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280–1287.
- Zakynthinos E, Kiropoulos T, Gourgoulianis K, Filippatos G. diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases. Heart Lung. 2008;37:275–285.
- Meyer B, Huelsmann M, Wexberg P, N-Terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med. 2007;35:2268–2273.
- Kotanidou A, Karsaliakos P, Tzanela M, prognostic importance of increased plasma amino-terminal pro-brain natriuretic peptide levels in a large noncardiac, general intensive care unit population. Shock. 2009;31:342–347.
- Francis GS, Benedict C, Johnstone DE, Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–1729.
- Castillo JR, Zagler A, Carrillo-Jimenez R, Hennekens CH. Brain natriuretic peptide: a potential marker for mortality in septic shock. Int J Infect Dis. 2004;8:271–274.
- Kumar A, Osman J. Septic myocardial depression: no “no” to NO? Crit Care Med. 2001;29:202–203.
- Court O, Kumar A, Parrillo JE, Kumar A. Clinical review: myocardial depression in sepsis and septic shock. Crit Care. 2002;6:500–508.
- Witthaut R, Busch C, Fraunberger P, Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med. 2003;10:1696–1702.
- Shor R, Rozenman Y, Bolshinsky A, BNP in septic patients without systolic myocardial dysfunction. Eur J Intern Med. 2006;17:536–540.
- Hughes WT, Armstrong D, Bodey GP, 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Infectious Diseases Society of America. Clin Infect Dis. 2002;34:730–750.
- Brueckmann M, Huhle G, Lang S, Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation. 2005;112:527–534.
- Varpula M, Pulkki K, Karlsson S, Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med. 2007;35:1277–1283.
- Rivers EP, McCord J, Otero R, Clinical utility of B-type natriuretic peptide in early severe sepsis and septic shock. J Intensive Care Med. 2007;22:363–373.
- Nikolaou NI, Goritsas C, Dede M, Brain natriuretic peptide increases in septic patients without severe sepsis or shock. Eur J Intern Med. 2007;18:535–541.
- Burjonroppa SC, Tong AT, Xiao, LC, Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload. Am J Clin Oncol. 2007;30:287–293.
- Hamalainen S, Juutilainen A, Kuittinen T, Serum amino-terminal pro-brain natriuretic peptide in hematological patients with neutropenic fever: a prospective comparison with C-reactive protein. Leuk Lymphoma. 2010;51:1040–1046.
- Yetkin O, Hacievliyagil SS, Gunen H. Assesssment of B-type natriuretic peptide in patients with pneumonia. Int J Clin Pract. 2008;62:488–491.
- Ueno H, Nakayama M, Kojima S, The synergistic combined effect of anemia with high plasma levels of B-type natriuretic peptide significantly predicts an enhanced risk for major adverse cardiac events. Heart Vessels. 2008;23:243–248.